J Neuroinflammation
Published

Alzheimer's disease-associated complement gene variants influence plasma complement protein levels.

Authors

Aurora Veteleanu, Joshua Stevenson-Hoare, Samuel Keat, Nikoleta Daskoulidou, Henrik Zetterberg, Amanda Heslegrave, Valentina Escott-Price, Julie Williams, Rebecca Sims, Wioleta M Zelek, Sarah M Carpanini, Bryan Paul Morgan
Read More

Abstract

Alzheimer's disease (AD) has been associated with immune dysregulation in biomarker and genome-wide association studies (GWAS). GWAS hits include the genes encoding complement regulators clusterin (CLU) and complement receptor 1 (CR1), recognised as key players in AD pathology, and complement proteins have been proposed as biomarkers.

PMID:37480051 | DOI:10.1186/s12974-023-02850-6

UK DRI Authors

Prof Henrik Zetterberg

Group Leader

Pioneering the development of fluid biomarkers for dementia

Prof Henrik Zetterberg
Amanda Heslegrave

Dr Amanda Heslegrave

Principal Research Fellow

Co-leading the UK DRI Biomarker Factory platform based at UK DRI at UCL

Dr Amanda Heslegrave

Prof Valentina Escott-Price

Group Leader

Using Big Data, machine learning and AI to accelerate discoveries into dementia

Prof Valentina Escott-Price

Prof Julie Williams

Group Leader

Understanding the genetics of Alzheimer's disease

Prof Julie Williams